Podcasts about Gilead

In a world competing for our attention, our guest this week admits: “It's probably harder to read novels now than it ever was.” But their value cannot be overstated. The novel's unique humanity, its careful and open treatment of the human experience, helps us to develop a sympathetic imagination, tuning our hearts and minds in a way that non-fiction argument simply cannot. Christopher Scalia, author of 13 Novels Conservatives Will Love (but Probably Haven't Read), makes the case that it is a distinctly conservative interest to explore the Western tradition through fiction. Recommendations in hand, he invites adults to refresh their reading list with novels—from the very inception of the form up to the present. Chapters: 1:47 The great book rut 4:11 Novels: the medium of recent Western tradition 5:30 The 18th-century bildungsroman 9:47 “Conservative” themes 16:18 The American dream in My Ántonia 22:39 Miraculous realism in Peace Like a River 29:02 Acknowledging the existence of evil 31:44 Wonder and encounter over strict interpretation 37:03 Revisiting works from your school years 38:47 Why narrative works 42:01 Books that nearly made the cut Links: 13 Novels Conservatives Will Love (but Probably Haven't Read) by Christopher Scalia Christopher J. Scalia at American Enterprise Institute The History of Rasselas by Samuel Johnson (1759) Evelina by Frances Burney (1778) Waverley by Sir Walter Scott (1814) The Blithedale Romance by Nathaniel Hawthorne (1852) Daniel Deronda by George Eliot (1876) My Ántonia by Willa Cather (1918) Their Eyes Were Watching God by Zora Neale Hurston (1937) The Girls of Slender Means by Muriel Spark (1963) The Children of Men by P. D. James (1992) Peace Like a River by Leif Enger (2001) Gilead by Marilynne Robinson (2004) The Road by Cormac McCarthy (2006) How I Won a Nobel Prize: A Novel by Julius Taranto (2023) Also on the Forum: Heights Forum Book Reviews On Reading Literature by Joseph Bissex Some Summer Reading Recommendations for Teachers by Tom Cox Modern Literature: On Curating the Contemporary featuring Mike Ortiz Guiding Our Boys through Modern Literature featuring Joe Breslin and Lionel Yaceczko Featured opportunities: Teaching Essentials Workshop at The Heights School (June 16-20, 2025) Convivium for Teaching Men at The Heights School (November 13-15, 2025)

THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)JOSH CHARLES The penultimate episode of The Handmaid's Tale (season 6 episode 9) wasn't just good—it was fantastic. Paul and Caroline are back with an energized breakdown of Episode 9, “Execution,” and they're thrilled to share their reactions with you. After years of suffering alongside these characters, this episode delivered some long-awaited justice and catharsis. Paul and Caroline loved every moment—but they still put on their podcasting hats to ensure the plot wasn't just emotionally satisfying, but also logically sound. Thankfully, "Execution" nailed both. THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)BRADLEY WHITFORD This week's podcast mirrors the intense pacing of the episode, taking you step-by-step through all the dramatic twists leading up to the unforgettable scenes at the gallows and the explosive start of the rebellion. From there, the discussion shifts toward Commander Lawrence's tense, fateful journey to the airport and the dramatic consequences that followed. THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)MAX MINGHELLA Paul and Caroline found this episode to be a nearly perfect balance of tension, emotional payoff, and narrative clarity—the kind of episode fans have waited seasons to see. Join them as they celebrate these pivotal moments and dissect every significant plot turn. THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)D'ARCY CARDEN, SAM JAEGER THE HANDMAID'S TALE Season 6 Episode 9- “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)SAMIRA WILEY Season 6: 601 | 602 | 603 | 604 | 605 | 606 | 607 | 608 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 | 510 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410+Bruce Miller Interview Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering: Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains Adriana leads the expansion of Pierre Fabre's US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy. Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week on The TV Dudes, Les is joined by actress Carey Cox, who portrays Rose Blaine in The Handmaid's Tale. Introduced in Season 5 as the wife of Nick, Rose is an unusual character in Gilead due to her visible disability — congenital hip dysplasia. This mirrors Carey's real-life experience living with Ehlers-Danlos Syndrome. As a disabled actor and advocate, Carey brings authenticity and nuance to her roles, challenging outdated perceptions of disability in the entertainment industry. We chat about her career path, her work on The Handmaid's Tale, and much more. #TheHandmaidsTale #CareyCox #TheTVDudes 

THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie). The revolution has begun. In The Handmaid's Tale Season 6 Episode 8 "Exodus", the carefully plotted rebellion against Gilead erupts during Serena Joy's wedding, shifting the tide of power in ways we've long hoped—and feared. On this week's podcast, Paul and Caroline unpack the episode's three central storylines and what they mean for the final stretch of the series. The episode unfolds through three distinct perspectives: Serena's Wedding:It's the centerpiece of the rebellion. The plan to bomb Jezebels has been replaced with something quieter but just as deadly: poison. Serena's maroon wedding cake becomes a focal point—rich in symbolism, according to Paul and Caroline, who debate its possible meanings. The poison weakens the guests, setting the stage for the handmaids to strike later that night. But what comes next for Serena? In the final scenes inside her and Wharton's new home, we're left wondering: Is she a survivor, a pawn, or a player? THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie)ELISABETH MOSS June's Command:June leads from the front, orchestrating the handmaids' infiltration and managing the rebellion in real time. Paul and Caroline discuss June's transformation into a true field general—steely, smart, and still deeply human. They also wrestle with the looming question: what does a “win” even look like for June at this point, and is it within reach? THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie)THE HANDMAID'S TALE Aunt Lydia's Reckoning:The final storyline brings us to Aunt Lydia, whose breaking point finally arrives at the Red Center. Surrounded by Janine and the other handmaids, she is forced to confront the consequences of her life's work. In her quiet moments and subtle gestures, a transformation begins—one that may redefine her future in Gilead. THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie)THE HANDMAID'S TALE With explosive action, raw emotion, and thematic depth, “Exodus” delivers a powerful step toward the endgame. Paul and Caroline are here to guide you through every decision, every cost, and every unanswered question. Season 6: 601 | 602 | 603 | 604 | 605 | 606 | 607 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Obadiah 10-21 (NASB) 10 "Because of violence to your brother Jacob, You will be covered with shame, And you will be cut off forever.11 "On the day that you stood aloof, On the day that strangers carried off his wealth, And foreigners entered his gate And cast lots for Jerusalem - You too were as one of them.12 "Do not gloat over your brother's day, The day of his misfortune. And do not rejoice over the sons of Judah In the day of their destruction; Yes, do not boast In the day of their distress.13 "Do not enter the gate of My people In the day of their disaster. Yes, you, do not gloat over their calamity In the day of their disaster. And do not loot their wealth In the day of their disaster.14 "Do not stand at the fork of the road To cut down their fugitives; And do not imprison their survivors In the day of their distress.The Day of the LORD and the Future15 "For the day of the LORD draws near on all the nations. As you have done, it will be done to you. Your dealings will return on your own head.16 "Because just as you drank on My holy mountain, All the nations will drink continually. They will drink and swallow And become as if they had never existed.17 "But on Mount Zion there will be those who escape, And it will be holy. And the house of Jacob will possess their possessions.18 "Then the house of Jacob will be a fire And the house of Joseph a flame; But the house of Esau will be as stubble. And they will set them on fire and consume them, So that there will be no survivor of the house of Esau," For the LORD has spoken.19 Then those of the Negev will possess the mountain of Esau, And those of the Shephelah the Philistine plain; Also, possess the territory of Ephraim and the territory of Samaria, And Benjamin will possess Gilead.20 And the exiles of this host of the sons of Israel, Who are among the Canaanites as far as Zarephath, And the exiles of Jerusalem who are in Sepharad Will possess the cities of the Negev.21 The deliverers will ascend Mount Zion To judge the mountain of Esau, And the kingdom will be the LORD'S. Outline of Part 1 (2 weeks ago):- Intro/background: A long family feud- God's assessment of Edom (Pride comes before a fall) (vv. 1:1‑9)This week's outline:- Gods indictment of Edom (You are your brothers keeper) (vv. 1:10‑14)- God's judgment on all haters (Those who curse Israel will be cursed) (vv. 1:15‑21

Power Up:Judges 11:1 Now Jephthah the Gileadite was a mighty man of valour, and he was the son of an harlot: and Gilead begat Jephthah. 2 And Gilead's wife bare him sons; and his wife's sons grew up, and they thrust out Jephthah, and said unto him, Thou shalt not inherit in our father's house; for thou art the son of a strange woman. 3 Then Jephthah fled from his brethren, and dwelt in the land of Tob: and there were gathered vain men to Jephthah, and went out with him. 4 And it came to pass in process of time, that the children of Ammon made war against Israel. 5 And it was so, that when the children of Ammon made war against Israel, the elders of Gilead went to fetch Jephthah out of the land of Tob: 6 and they said unto Jephthah, Come, and be our captain, that we may fight with the children of Ammon. 7 And Jephthah said unto the elders of Gilead, Did not ye hate me, and expel me out of my father's house? and why are ye come unto me now when ye are in distress? 8 And the elders of Gilead said unto Jephthah, Therefore we turn again to thee now, that thou mayest go with us, and fight against the children of Ammon, and be our head over all the inhabitants of Gilead. 9 And Jephthah said unto the elders of Gilead, If ye bring me home again to fight against the children of Ammon, and the LORD deliver them before me, shall I be your head? 10 And the elders of Gilead said unto Jephthah, The LORD be witness between us, if we do not so according to thy words. 11 Then Jephthah went with the elders of Gilead, and the people made him head and captain over them: and Jephthah uttered all his words before the LORD in Mizpeh., King James VersionIn this episode, we are seeking the Lord on behalf of several right now issues that we are facing on this earth. We are praying for our children, our parents, our loved ones that are suffering with sicknesses, and we are lifting up our leaders. Thank you for being a supporter of this podcast as I grow and learn things will become more like previous episodes, but I do not want to delay the podcast while I learn how to use the new format. Thank you for all of your support. Thank you for your shares. Thank you for joining your faith with my faith so that we can see God move upon the face of the earth if you have a prayer request, you can text 843-790-4229 or submit it by email to seeingwithoutseeing2020@gmail.com. Please put prayer request in the subject line. That email address can be used on Zelle and PayPal. If you desire to sow a seed, you can do that also on cash app at $seeingwithoutseeing. Thank you once again for your support please share this and believe God with us as we seek God.

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. •    Intro :24 •    The interview/about Stidham :36 •    Tell us about your family and where you grew up. 1:14 •    How did you embrace changes in technology growing up? 3:07 •    What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator?  6:05 •    What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 •    Can you give a quick overview of what these tools and technologies entail?  12:52 •    What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 •    Where did your interest in AI come about? 20:26 •    You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 •    How do we change the way we train GI doctors, and should we start making these changes today? 26:38 •    With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 •    What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 •    What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 •    Thank you, Ryan 44:04 •    Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Accreditation/Credit Designation Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours. Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today's faculty are: Neeraj Agarwal, MD, FASCO Professor of Medicine Senior Director for Clinical Research HCI Presidential Endowed Chair of Cancer Research Director, Center of Investigational Therapeutics Director, Genitourinary Oncology Program Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Disclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-con Himisha Beltran, MD Associate Professor of Medicine Director of Translational Research Within Medical Oncology Harvard Medical School Lank Center for Genitourinary Oncology and the Division of Molecular and Cellular Oncology Dana Farber Cancer Institute Boston, MA Disclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, Novartis Maha Hussain, MD, FACP, FASCO Genevieve E. Teuton Professor of Medicine Professor, Medicine (Hematology/Oncology) Deputy Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL Disclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, Bayer The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity. Release Date May 14, 2025 Expiration Date May 14, 2026

President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episode 608 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her.              Host: Angelica Monk and Stacey Yvonne Music by: Sammus Edited by: Jamie Broadnax

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The White House has announced a new drug pricing policy that includes the revival of the most favored nations rule and extends to the private markets, leveraging the patent system, drug importation, and more. Meanwhile, Lilly's Zepbound has been found to have a superior benefit-risk ratio compared to Novo's Wegovy, BMS and Sanofi settle a Plavix lawsuit with Hawaii for $700 million, and biopharma companies are focusing on developing a cure for HIV as federal funding for related research is being cut. Sino Biological offers comprehensive solutions for autoimmune diseases, and Roche promises a $300 million investment in China production after a multibillion-dollar investment in the US. On the other hand, Lexeo and IGM have both announced significant layoffs. Novartis CEO has expressed concerns about Trump's pricing controls.Funding for HIV-related research and infrastructure is being cut by the Trump administration, leading biopharma companies like Gilead and Immunocore to focus on finding a cure for HIV. In the field of neurology, there is a need for more precise diagnostic tools to effectively treat neurodegenerative conditions. The new HHS vaccine requirement has been criticized by leading vaccine physician Paul Offit as potentially being anti-vaccine activism disguised as policy. Companies like Novartis, Bayer, and AstraZeneca are exploring new indications and innovations in radiopharmaceuticals, hoping to capitalize on a market that could reach $16 billion by 2033. The FDA has faced delays in reviewing certain drugs, while biotech stocks have fallen after the appointment of Vinay Prasad to succeed Marks at CBER. Vertex has decided to abandon AAV in the gene therapy space.Upcoming events include a webinar on surviving and thriving in the biotech downturn. Job opportunities in the biopharma industry include positions at Takeda, Daiichi Sankyo, and AbbVie. Heather McKenzie, senior editor at BioSpace, is open to suggestions for future coverage topics in neuroscience, oncology, cell & gene therapy, metabolic, or other areas.

On the surface, it was the perfect scam: kickbacks to docs in exchange for public speaking engagements, in order to induce them to prescribe drugs.That's apparently what Gilead Sciences thought.But a whistleblower blew the whistle, and Gilead admitted to paying hundreds of thousands of dollars to high prescribers of their HIV drugs to serve as speakers at programs at luxury restaurants.Famed whistleblower attorney Mary Inman, partner at Whistleblowers Partners, LLP, will report the savory details during the new live edition of Monitor Mondays, coming up at 10 a.m. EST on Monday, May 12.The long-running broadcast will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Folan Houston, assistant general counsel for Zelis, will report on the news at the intersection of healthcare and congressional action.• Field Report: Dr. Drew Updike continues his reporting on recent efforts by the Trump Administration to prevent providers from undertaking gender-affirming treatments for America's LGBTQ+ population.

Deuteronomy 34 is the final chapter of the book and brings closure to the life of Moses, the servant of God. It is a deeply emotional and reverent moment in the biblical narrative. ⸻ Key Highlights: 1. Moses Views the Promised Land (Verses 1–4): God leads Moses to the top of Mount Nebo, to a peak called Pisgah, across from Jericho. From there, the Lord shows him the entire land—Gilead, Naphtali, Ephraim, Manasseh, Judah, and all the way to the Mediterranean Sea. Though Moses is allowed to see the land, God tells him he will not enter it. 2. Moses Dies on Mount Nebo (Verse 5): Moses, the servant of the Lord, dies in Moab, just as the Lord said. His death is peaceful and divinely timed—not from illness or battle, but under God's hand. 3. God Buries Moses (Verse 6): God Himself buries Moses in a valley in Moab. To this day, the location of his grave remains unknown. This mysterious burial reflects Moses' unique relationship with God. 4. Moses Was Still Strong (Verse 7): At 120 years old, Moses' eyes were not weak, and his strength was not gone. He died with full vitality—showing that it was purely God's decision to bring his life to a close. 5. Israel Mourns (Verse 8): The Israelites wept for Moses in the plains of Moab for thirty days, marking a full mourning period, and honoring their leader who had guided them for decades. 6. Joshua Succeeds Moses (Verses 9–12): Joshua is filled with the spirit of wisdom because Moses had laid hands on him. The people listen to him, and the transition of leadership is affirmed. The chapter closes by honoring Moses: “Since then, no prophet has risen in Israel like Moses, whom the Lord knew face to face.” Moses had performed great signs, wonders, and miracles, and led Israel with unmatched courage, humility, and divine authority.Become a supporter of this podcast: https://www.spreaker.com/podcast/sendme-radio--732966/support.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Takeda's $30 billion investment in the U.S. is making headlines, along with their opposition to Trump's proposal on drug prices. The FDA's appointment of Vinay Prasad is stirring up mixed reactions within the industry. On another note, Lilly's legal victory against compounders, Novavax's growing sales, and Gilead's significant investment in U.S. manufacturing are all key developments. The FDA vaccine advisors are gearing up for a meeting to discuss COVID-19 updates, while Vor Bio is seeking an exit due to funding challenges. Biotech stocks took a hit following Prasad's appointment to lead CBER, highlighting the industry's current challenges including vaccine hesitancy and job market struggles.

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episode 607 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her. Host: Angelica Monk and Stacey Yvonne Music by: Sammus Edited by: Jamie Broadnax

In a new installment of the Critics at Large advice hotline, Vinson Cunningham, Naomi Fry, and Alexandra Schwartz field calls from listeners on a variety of cultural dilemmas, and offer recommendations for what ails them. Callers' concerns run the gamut from the lighthearted to the existential; several seek works to help ease the sting of the state of the world. “I can't say that we will solve those deeper issues,” Cunningham says. “But to share art with somebody is to offer them a companion.”Read, watch, and listen with the critics:The New York Issue of The New Yorker (May 12 & 19, 2025)“Birds of America,” by Lorrie Moore“Eighth Grade” (2018)“Gilead,” by Marilynne Robinson“Danny, the Champion of the World,” by Roald Dahl“Midnight Diner” (2016-19)“Sentimental Education,” by Gustave Flaubert“Middlemarch,” by George Eliot“My Life in Middlemarch,” by Rebecca Mead“How the Method Made Acting Modern,” by Alexandra Schwartz (The New Yorker)Charles Schulz's “Peanuts”“First Reformed” (2017)“Better Things” (2016-22)“The Functionally Dysfunctional Matriarchy of ‘Better Things,' ” by Alexandra Schwartz (The New Yorker)“Odes,” by Sharon OldsTJ Douglas's “Dying”Mozart's “The Magic Flute”“Peppa Pig” (2004—)Aaron Copland's “Billy the Kid”Dennis Wilson's “Pacific Ocean Blue”Caetano Veloso's “Ofertório”Crosby, Stills & Nash's début albumNew episodes drop every Thursday. Follow Critics at Large wherever you get your podcasts. Learn about your ad choices: dovetail.prx.org/ad-choices

Hey there, welcome back to the Gilead podcast. And WELCOME to the final sermon of Gilead! With a last will & testament, pomp & circumstance, on May 4, 2025, we closed the church. The Reverend Rebecca Anderson preached this final service. And members of the service read our Last Will & Testament to the congregation, which we then signed. It was a memorable night. And you can listen to it! Right here! ******We've been Gilead Chicago, a queer storytelling bar church located on Chicago's north side. As of May 4th, 2025, we're closed, but these episodes will stay online. So come join us whenever you need a little storytelling, a little perspective, a little prayer. 

The Beckham family feud is making headlines again, huns, after Brooklyn missed David's starry 50th bash – the latest in a long line of similar ‘snubbed' events. He didn't even post about his dad's big day, so might this genuinely be more than tabloid rumour? Obvs we're debriefing on the Met Gala too, from Rihanna's pregnancy reveal to the apparent fall out between Anna Wintour and Naomi Campbell. Also this week: Dolly Alderton's new quotes on friendship, Tina Fey's ‘mid-life' comedy The Four Seasons and our review of the first ep of the final series of The Handmaid's Tale. Enjoy and please do leave us a review on Apple Podcasts or a rating on Spotify – it really does help keep us going!We love hearing from you, DM us ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@straightuppod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or email at ⁠⁠hello@straightuppodcast.co.uk⁠Huge thanks to our sponsor⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Yonder⁠⁠⁠⁠⁠⁠⁠⁠, the incredible lifestyle rewards credit card packed with rewards you'll actually *want* to use. Find out more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠yonder.com/straightup⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Borrow responsibly. £15 a month. 18+ and UK only. Rep 66.3% APR var. T&Cs apply.Get 20% off the adaptogenic coffee that changed our lives, London Nootropics, using our code straightup at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠londonnootropics.com⁠⁠⁠Try BookBeat for 60 days for free and stream millions of audio and e-books using our code straightup at bookbeat.comGet better skin and sleep with sisterly's amazing Elevator powder multivit sachet and use our code STRAIGHTUP for 15% off at sisterlylab.co.ukRecs:Slags by Emma Jane UnsworthNaomi Campbell's charity ended in disgrace. She wants to talk about why, Financial TimesSally Rooney, Naomi Campbell and Nobody Wants This, Straight Up ep Oct 24The Four Seasons, Netflix The Handmaid's Tale, Amazon Prime/ C4 As the curtain falls on Gilead, is The Handmaid's Tale too close to the bone? The IndependentThe MaddAddam Trilogy, Margaret Atwood Make Christianity cool again: Why Gen Z is flocking to church, The Independent . Hosted on Acast. See acast.com/privacy for more information.

Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

THE HANDMAID'S TALE Season 6 Episode 7 - “Shattered” - After a shocking revelation, June spirals. Serena plans for a prestigious future. (Disney/Steve Wilkie)YVONNE STRAHOVSKI The fallout from Nick's betrayal shakes every corner of Gilead—and The Handmaid's Tale delivers one of its most emotionally charged episodes yet. Paul and Caroline are back to break it all down. “Shattered” picks up immediately after last week's shocking ending. June is forced to silently listen as Commander Wharton details Nick's betrayal to Serena. Meanwhile, Jezebels becomes a massacre site: the workers are rounded up and executed, with Janine alone spared—with the nasty Commander Bell as her benefactor. THE HANDMAID'S TALE Season 6 Episode 7 - “Shattered” - After a shocking revelation, June spirals. Serena plans for a prestigious future. (Disney/Steve Wilkie)D'ARCY CARDEN June and Nick share a tense, painful car ride toward the border. Nick tries to justify his actions, claiming June never understood the risks he carried in Gilead. But June isn't interested in apologies. She leaves him behind, striding toward the rebel base—and toward a life without Nick in it. Back in New Bethlehem, Serena faces ridicule from the other Wives at her bridal shower. She demands a grander wedding from Wharton, who agrees but insists that Handmaids be part of the guest list—a decision that will have explosive consequences. THE HANDMAID'S TALE Season 6 Episode 7 - “Shattered” - After a shocking revelation, June spirals. Serena plans for a prestigious future. (Disney/Steve Wilkie)MADELINE BREWER At the Mayday base, June confesses her role in the failed Jezebel's mission, costing her standing among the rebels. But when Commander Lawrence visits, June realizes that Serena's wedding offers a rare opportunity. A new plan quickly forms. The episode ends with a pulse-pounding montage: poison is delivered to Rita, who will be baking Serena's wedding cake. Moira and June are hidden among the Handmaids at the Red Center, preparing to arm the women for what's coming next. THE HANDMAID'S TALE Season 6 Episode 7 - “Shattered” - After a shocking revelation, June spirals. Serena plans for a prestigious future. (Disney/Steve Wilkie)JOSH CHARLES, YVONNE STRAHOVSKI In this podcast episode, we dive into: The emotional rift between June and Nick Serena's power plays and how they backfire Janine's mysterious survival And the rebels' daring plan for what should be Gilead's biggest uprising yet Season 6: 601 | 602 | 603 | 604 | 605 | 606 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

Hosea 6:1-11A Confession of Trust6  “In their affliction they will rise up early toward me, saying, ‘Let us go and return to the Lord, our God, because he has snatched away, and he will heal us. He will strike, and he will bandage us. 2  He will restore us to health after two days; on the third day we will rise and live before him, 3  and we will know; we will seek to know the Lord. Like the sure-to-come dawn we will find him, and he will come to us like the early and late rain comes to the earth.' ” Israel's Transgressions4  “What will I do with you, O Ephraim? What will I do with you, O Judah? Your mercy is like an early morning cloud, and like an early dew that is going away. 5  On account of this, I cut off your prophets; I killed them with a word from my mouth, and my judgment will go out like light. 6  Because I want mercy rather than sacrifice, and knowledge of God rather than whole burnt offerings. 7  But they are like a person breaking a treaty; there he despised me. 8  Gilead is a city doing vain things, stirring up water. 9  And your strength is that of a pirate man. Priests hid the way. They killed Shechem, because they did lawlessness. 10  In the house of Israel I saw a horrible thing. There was the fornication of Ephraim; Israel and Judah were defiled. 11  Begin to reap for yourself when I return the captives of my people,   when I heal Israel. Rick Brannan, Ken M. Penner et al., The Lexham English Septuagint, Second Edition (Bellingham, WA: Lexham Press, 2020), Ho 6:1–11

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Daniel Eckert über zwei Gipfelstürmer im Dax, das 20.000-Punkte-Comeback des Nasdaq und was diese Woche sonst noch wichtig wird. Außerdem geht es um Rheinmetall, Siemens, Siemens Energy, Münchener Rück, RWE, BASF, Aixtron, Berkshire Hathaway, Novo Nordisk, Eli Lilly, Pfizer, Merck KGaA, Viking Therapeutics, Gilead, Regulus Therapeutics, SpringWorks Therapeutics, Nuvalent, Legend Biotech, Dexcom, Arcellx, Blueprint Medicines, Roche und Johnson&Johnson. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Sin can only gain the appearance of victory, so we must not be deceived. Instead, we must remember that God has the ultimate victory over sin. Genesis 37:18–34 (ESV): 18 They saw him from afar, and before he came near to them they conspired against him to kill him. 19 They said to one another, “Here comes this dreamer. 20 Come now, let us kill him and throw him into one of the pits. Then we will say that a fierce animal has devoured him, and we will see what will become of his dreams.” 21 But when Reuben heard it, he rescued him out of their hands, saying, “Let us not take his life.” 22 And Reuben said to them, “Shed no blood; throw him into this pit here in the wilderness, but do not lay a hand on him”—that he might rescue him out of their hand to restore him to his father. 23 So when Joseph came to his brothers, they stripped him of his robe, the robe of many colors that he wore. 24 And they took him and threw him into a pit. The pit was empty; there was no water in it. 25 Then they sat down to eat. And looking up they saw a caravan of Ishmaelites coming from Gilead, with their camels bearing gum, balm, and myrrh, on their way to carry it down to Egypt. 26 Then Judah said to his brothers, “What profit is it if we kill our brother and conceal his blood? 27 Come, let us sell him to the Ishmaelites, and let not our hand be upon him, for he is our brother, our own flesh.” And his brothers listened to him. 28 Then Midianite traders passed by. And they drew Joseph up and lifted him out of the pit, and sold him to the Ishmaelites for twenty shekels of silver. They took Joseph to Egypt. 29 When Reuben returned to the pit and saw that Joseph was not in the pit, he tore his clothes 30 and returned to his brothers and said, “The boy is gone, and I, where shall I go?” 31 Then they took Joseph's robe and slaughtered a goat and dipped the robe in the blood. 32 And they sent the robe of many colors and brought it to their father and said, “This we have found; please identify whether it is your son's robe or not.” 33 And he identified it and said, “It is my son's robe. A fierce animal has devoured him. Joseph is without doubt torn to pieces.” 34 Then Jacob tore his garments and put sackcloth on his loins and mourned for his son many days.

Yvonne Strahovski says it herself. “She's hateable.” Serena's run throughout The Handmaid's Tale is absolutely littered with questionable and, in some cases, heinous decisions. But, this is the power of a force like Strahovski. Sometimes, in between terrible choices, Serena will get an opportunity to turn to the light, and even after everything she's done, you can't help but hope she finally reaches out, takes the lifeline, and forges a better path forward. However, time and time again, she back pedals and becomes consumed by self-righteousness, often at others' expense, and Season 6 is no different.At the top of the Emmy-winning series' sixth and final season, Serena was close to finding a way out. She winds up on a train to Alaska with June (Elisabeth Moss) where she can get a fresh start with Noah. However, old habits die hard and her behavior ultimately exposes her identity and turns the train passengers into an angry mob. Thanks to June, she manages to escape the riot, but rather than continue her pursuit of a new path forward, she returns to Gilead to settle in Commander Lawrence's (Bradley Whitford) New Bethlehem. While she's promised things will be different there, it quickly becomes clear that that's not the case, something Serena's own leadership tactics perpetuate.With The Handmaid's Tale nearing its big finish, Strahovski returned to Collider Ladies Night to dig into some of Serena's biggest moments in this final go-around, and to reflect on her experience tackling the character for six seasons. Hosted on Acast. See acast.com/privacy for more information.

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episode 606 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her. Hosts: Angelica Monk and Stacey Yvonne  Music by: Sammus Edited by: Jamie Broadnax

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie, a pharmaceutical company, has criticized President Trump's drug pricing proposal despite reporting strong earnings this quarter. The company is facing challenges with declining sales of its drug Humira and a struggling aesthetics business. Meanwhile, Gilead is moving forward with the launch of its HIV drug despite macro pressures in the industry. FDA Commissioner Marty Makary's recent statements have been fact-checked, with some contradictions emerging.In other news, SpringWorks is potentially being bought out by Merck KGaA for $3.5 billion. Wacker Biotech is offering services for advanced therapies. Stay tuned for more updates on these developments in the pharmaceutical and biotech sectors.

Apple (AAPL) is expected to double its iPhone output from India to 80 million. Diane King Hall says the company is bracing to maneuver its production around tariffs aimed at China. On earnings, T-Mobile (TMUS) lagged compared to peers when its customer additions didn't meet expectations. Diane also turns to Gilead's (GILD) earnings, which showed pockets of strength that face pressures in a shifting healthcare sector. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Earnings roll in from Alphabet, Intel, Gilead, and more as earnings season rolls on. The Fast Money traders break down the numbers and where they see those stocks heading next. Deepwater Asset's Gene Munster joins to dig into the big themes around the tech. Plus, China responds to Trump's latest tariff threats, as contradictory comments come out of both parties. Fast Money Disclaimer

As CEO of Porter Novelli, Jillian Janaczek manages talent and operations of the strategic communications company globally, nurturing key client relationships, and driving business growth across Health, Corporate + Brand, Food + Ag + Nutrition, Purpose + Impact, Tech, and Government, as well as strategic services. She is part of OPRG's (Omnicom PR Group's) global leadership team. ​ Before Porter Novelli, Janaczek was President, BCW New York, spearheading the firm's largest market and managing Fortune 500 clients. She sat on BCW's Global Board and was Chair, Client Risk Committee. ​Earlier in her career, Janaczek was Managing Director of Healthcare at Cohn & Wolfe. Her background includes extensive work with prescription medications and Rx to OTC switches. She has worked closely with leading companies such as AbbVie, GlaxoSmithKline, Gilead, Johnson & Johnson, Merck, Novartis and Novo Nordisk, among many others, providing strategic counsel for U.S. and Global programs. She expanded her role with Novartis Pharma AG by working in-house as Global Brand Manager in Basel, Switzerland. ​

This episode covers: Cardiology This Week: A concise summary of recent studies Hypertension in the elderly The digital twin in cardiology Snapshots Host: Emer Joyce Guests: Carlos Aguiar, Gianfranco Parati, Nico Bruining, Joost Lumens Want to watch that episode? Go to: https://esc365.escardio.org/event/1804 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Merck, Viatris, Somnomedics. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Joost Lumens and Nico Bruining Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1804?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episode 605 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her. Hosts: Angelica Monk and Stacey Yvonne  Music by: Sammus Edited by: Jamie Broadnax

THE HANDMAID'S TALE Season 6 Episode 5 - “Janine” - June and Moira go undercover. Serena and Nick make consequential choices. (Disney/Steve Wilkie)SAMIRA WILEY, MADELINE BREWER, ELISABETH MOSS Episode 5, “Janine,” delivers an intense, high-stakes hour as our characters inch deeper into danger with every move. In this week's podcast, Paul and Caroline break down the chaos, consequences, and shifting alliances. June and Moira are back in the field, attempting a “dry run” infiltration of Jezebels. They do manage to meet with Janine and pass along vital information—but their personal friction throws a wrench in the timing. When they're forced to kill a predatory guardian and cover it up, things spiral fast. By the time they return to their rendezvous point, Luke has been threatened and driven off by another guardian. Now June and Moira are trapped inside Jezebels—with no clear way out. THE HANDMAID'S TALE Season 6 Episode 5 - “Janine” - June and Moira go undercover. Serena and Nick make consequential choices. (Disney/Steve Wilkie)O-T FAGBENLE Their only salvation comes in the form of a chance run-in with Commander Lawrence, who unexpectedly clears a path for their escape. But the damage is done: Luke's original plans are ruined, and June and Moira are still stuck in Gilead. Elsewhere, Nick handles his own grim task—finishing the job he started in no man's land. One of the guardians from the escape has survived, and loose ends aren't something Nick can afford. Meanwhile, Serena Joy receives a surprising push from Aunt Lydia: a nudge toward Commander Wharton. By episode's end, Wharton proposes—with Serena negotiating several key terms. It's not a love story—it's a power move. THE HANDMAID'S TALE Season 6 Episode 5 - “Janine” - June and Moira go undercover. Serena and Nick make consequential choices. (Disney/Steve Wilkie)YVONNE STRAHOVSKI, JOSH CHARLES In this episode of the podcast, we dive into the shifting power dynamics, the costs of personal conflict in a resistance movement, and Janine's continuing importance to the emotional heart of the series. Season 6: 601 | 602 | 603 | 604 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Roche and Regeneron are both investing heavily in US manufacturing, with Roche committing $50 billion and Regeneron signing a $3 billion deal with Fujifilm. This move comes as Trump's tariffs threaten the industry. Meanwhile, Pfizer, Alnylam, and BridgeBio are competing in the market for ATTR-CM treatment, with Alnylam and BridgeBio vying for patients switching from Pfizer's tafamidis drug and all three companies seeking new patients.Novo Nordisk has filed for FDA approval of an oral weight loss pill, AstraZeneca and Daiichi Sankyo are pushing their drug Enhertu for frontline breast cancer treatment, and Gilead's Trodelvy in combination with Keytruda has shown promise in slowing disease progression in triple-negative breast cancer. Wacker Biotech is offering services for advanced therapies, while Tempest has recently laid off 80% of its workforce.The industry is facing regulatory challenges and economic uncertainty, with Trump's tariffs potentially impacting pharma companies. Lilly has promised to manufacture a weight-loss pill in the US following a phase III win, and Makary discusses rare disease approvals and public distrust in a new interview. Biotech's future may be more focused on American companies according to PitchBook.

433. The Road to Gilead with Dan Schreiber, Mara Clarke, Dr Felicia Yeung and Neil DattaThe Guilty Feminist 433. The Road to GileadPresented by Deborah Frances-White with special gusts Dan Schreiber, Mara Clarke, Dr Felicia Yeung and Neil DattaRecorded 9 April 2025 at The Bath Komedia. Released 21 April.The Guilty Feminist theme composed by Mark Hodge. Get Deborah's new book with 30% off using the code SIXCONVERSATIONSPOD https://store.virago.co.uk/products/six-conversations-were-scared-to-haveMore about Deborah Frances-Whitehttps://deborahfrances-white.comhttps://www.instagram.com/dfdubzhttps://www.virago.co.uk/titles/deborah-frances-white/six-conversations-were-scared-to-have/9780349015811https://www.virago.co.uk/titles/deborah-frances-white/the-guilty-feminist/9780349010120More about Dan Schreiberhttps://www.instagram.com/schreiberlandhttps://linktr.ee/schreiberlandMore about Mara Clarkehttps://www.instagram.com/mara.k.clarkehttps://www.supportingabortions.euMore about Dr Felicia Yeunghttps://www.instagram.com/drfelyeunghttps://reprojusticeinitiative.orgMore about Neil Dattahttps://www.epfweb.org/node/73Mara's slides – where to goUK-based@reprojusticeinitiative @adiyahcollective @abortionsupportnetworkEuropeS.A.F.E. @supportingabortions4everUSA@abortioneverydayabortionfunds.org/find-a-fundFor more information about this and other episodes…visit https://www.guiltyfeminist.comtweet us https://www.twitter.com/guiltfempodlike our Facebook page https://www.facebook.com/guiltyfeministcheck out our Instagram https://www.instagram.com/theguiltyfeministor join our mailing list http://www.eepurl.com/bRfSPTOur new podcasts are out nowMedia Storm https://podfollow.com/media-stormAbsolute Power https://podfollow.com/john-bercows-absolute-powerCome to a live recording:An Evening with Deborah Frances-White and David Tennant https://www.intelligencesquared.com/events/an-evening-with-deborah-frances-white-and-david-tennantThank you to our amazing Patreon supporters.To support the podcast yourself, go to https://www.patreon.com/guiltyfeminist You can also get an ad-free version of the podcast via Apple Podcasts or Acast+ https://plus.acast.com/s/guiltyfeminist. Hosted on Acast. See acast.com/privacy for more information.

Welcome to Day 2613 of Wisdom-Trek. Thank you for joining me. This is Guthrie Chamberlain, Your Guide to Wisdom Day 2613 – Wisdom Nuggets – Psalm 60:1-12 – Daily Wisdom Wisdom-Trek Podcast Script - Day 2613 Welcome to Wisdom-Trek with Gramps! I am Guthrie Chamberlain, and we are on Day 2613 of our Trek. The Purpose of Wisdom-Trek is to create a legacy of wisdom, to seek out discernment and insights, and to boldly grow where few have chosen to grow before. In today's Wisdom Nugget, I'll be your guide on this insightful journey through the timeless truths found in God's Word. Together, we'll explore the depths of Scripture to uncover wisdom for everyday life. It's a joy to have you join me again today as we continue our meaningful journey through the Psalms. Today's trek brings us to Psalm 60, a unique and powerful Psalm. Psalm 60 is intriguing because it addresses a time of national crisis in ancient Israel—a time when King David's military campaigns faced unexpected setbacks, leaving Israel feeling vulnerable and abandoned. Yet even amidst these disappointments, Psalm 60 shows how the Israelites wrestled with their circumstances, honestly lamented their confusion, and ultimately placed their hope in God alone. Let's journey together through Psalm 60:1-12 from the New Living Translation. Listen closely as we unpack its truths verse by verse: Psalm 60:1-12 (NLT) 1 You have rejected us, O God, and broken our defenses. You have been angry with us; now restore us to your favor. 2 You have shaken our land and split it open. Seal the cracks, for the land trembles. 3 You have been very hard on us, making us drink wine that sent us reeling. 4 But you have raised a banner for those who fear you— a rallying point in the face of attack. 5 Now rescue your beloved people. Answer and save us by your power. 6 God has promised this by his holiness: “I will divide up Shechem with joy. I will measure out the valley of Succoth. 7 Gilead is mine, and Manasseh, too. Ephraim, my helmet, will produce my warriors, and Judah, my scepter, will produce my kings. 8 But Moab, my washbasin, will become my servant, and I will wipe my feet on Edom and shout in triumph over Philistia.” 9 Who will bring me into the fortified city? Who will bring me victory over Edom? 10 Have you rejected us, O God? Will you no longer march with our armies? 11 Oh, please help us against our enemies, for all human help is useless. 12 With God's help we will do mighty things, for he will trample down our foes. A Heartfelt Lament: Feeling Abandoned (Verses 1-3) David opens Psalm 60 with raw honesty about Israel's crisis: “You have rejected us, O God, and broken our defenses. You have been angry with us; now restore us to your favor. You have shaken our land and split it open. Seal the cracks, for the land trembles. You have been very hard on us, making us drink wine that sent us reeling.” These words capture the Israelites' deep sense of abandonment and confusion. David and the nation experienced surprising military defeats—losses they never expected. Notice how directly David speaks to God—he does not soften his words or hide his pain. In the ancient Israelite worldview, national victories indicated God's favor, while defeats suggested divine displeasure. David understands clearly that God has allowed these difficulties, yet he boldly asks God to restore them,...

Message Notes for Today's Sermon. Click Here - https://gileadchurch.churchcenter.com/episodes/463407/notes Outline for Today's Sermon. Click Here - https://www.gileadchurch.com/wp-content/uploads/4-20-25.pdf Digital Connection Card Click Here to fill one out - https://gileadchurch.churchcenter.com/people/forms/202250 Having Trouble with the Live Stream? Click Here to watch on our website - https://www.gileadchurch.com/ Looking to Give Online? Click Here - https://www.gileadchurch.com/giving/ Did you make a decision today and want to take your Next Step? Click Here - https://www.gileadchurch.com/next-steps/ To Listen to Our Podcasts: Apple: https://podcasts.apple.com/.../gilead-church.../id322393078 Spotify: https://open.spotify.com/show/0sOidhOjzZepJFlQp2ZJWZ... Google: https://podcasts.google.com?feed=aHR0cHM6Ly9oZWFsaW5ndG91Y2hwb2RjYXN0LmxpYnN5bi5jb20vcnNz For More From Gilead Church: http://www.gileadchurch.com/ https://www.facebook.com/gileadchurch1/ https://www.instagram.com/gilead_church/

Summary of Judges 10:Judges 10 introduces two minor judges, Tola and Jair, who led Israel after Abimelech's violent reign.Tola, from the tribe of Issachar, judged Israel for 23 years and lived in Shamir in Ephraim.Jair, from Gilead, judged for 22 years. He had 30 sons who rode 30 donkeys and controlled 30 towns in Gilead.After Jair's death, Israel once again turned away from God, worshiping the Baals and foreign gods. In response, God allowed them to be oppressed by the Philistines and Ammonites.The Israelites cried out in repentance.God reminded them of all the times He had rescued them despite their disobedience.He initially refused to help but their sincere repentance and abandonment of idols moved Him.The chapter ends with Israel preparing for battle against the Ammonites, while seeking a leader.Your words were found and I ate them

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episodes 603 and 604 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her. Hosts: Angelica Monk and Stacey Yvonne  Music by: Sammus Edited by: Jamie Broadnax

The Handmaid's Tale Season 6 Episode 4 "Promotion". Luke (O-T Fagbenle) and June (Elisabeth Moss). Image by Hulu. Copyright 2025. In The Handmaid's Tale Season 6 Episode 4, “Promotion,” sees the battle lines blur as loyalties shift, personal stakes rise, and unexpected reunions shake long-held beliefs. Paul and Caroline are back on the podcast to unpack every twist. In this episode, June finds out just how deep Luke and Moira have gotten with Mayday. They're not just helping—they're leading an upcoming bombing operation. June begs them to leave with her, to put safety first and return to Alaska—but when they won't, she takes matters into her own hands. She forces her way into their plans, determined to protect them, even if it means pushing them away. The Handmaid's Tale Season 6 Episode 4 "Promotion". Moira (Sonequa Martin-Green). Image by Hulu. Copyright 2025. Meanwhile in Gilead, Commander Lawrence receives a career-defining promotion to High Commander. His celebration takes place at Jezebels—darkly ironic, given the setting. There, he shares a quiet, emotional moment with Janine, offering her a drawing from her daughter Angela. It's a rare crack in the armor for both of them. Over in New Bethlehem, Rita reenters the picture, bringing her quiet strength to Nick's doorstep. She needs his help smuggling her family out of Gilead, and the only way may be through the cracks in Lawrence's new kingdom. The Handmaid's Tale Season 6 Episode 4 "Promotion". Luke (O-T Fagbenle). Image by Hulu. Copyright 2025. In this episode of the podcast, we explore the meaning of power—who has it, who uses it, and who pays the price. “Promotion” continues to build momentum toward what feels like an inevitable reckoning. Season 6: 601 | 602 | 603 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

In the final chapter of June Osborne's fight against Gilead, the stakes have never been higher. For both sides. Will justice and freedom ever prevail?Join Brittany and Amber of OllivAmber's Wands as we discuss the first three episodes of the final season of Margaret Atwood's novel, The Handmaid's Tale. #TheHandmaidsTale #PraiseBeThe Handmaid's Tale (2017) is the Hulu Original series starring Elisabeth Moss, Yvonne Strahovski, Ann Dowd, Madeline Brewer, Max Minghella, O-T Fagbenle, and Bradley Whitford.Subscribe to OllivAmber's Wands:https://www.youtube.com/channel/UC5utepPfYkwxaG7ph5CcgiAFollow OllivAmber's Wands on Instagram:https://www.instagram.com/ollivambers.wands/Subscribe, rate and review! Follow The Watchers in the Basement on social media! Use #WatchersBasement to comment about the show!facebook.com/watchersbasementtwitter.com/WatchBasement instagram.com/watchersbasementthreads.net/@watchersbasementanchor.fm/watchersbasement

Continuing our theme of Everything Must Go, Rebecca preaches about ridding ourselves of physical objects. And why we might hold onto them in the first place. SUPPORTAs we continue to have services and celebrations so that we can close Gilead with celebration and joy, we still could always use your support. You can support at ⁠⁠⁠⁠⁠this GiveButter site⁠⁠⁠⁠⁠ to help with closing and funeral costs. Any and all donations will go towards providing an incredible final chapter to our congregants and listeners before we close this spring. JOIN OUR JOURNEY ONLINETo stay updated on Gilead's journey to close and read as members of the community share stories from their time with Gilead, you can follow our ⁠⁠⁠⁠⁠CaringBridge page⁠⁠⁠⁠⁠. If you'd like to contribute memories or stories of Gilead, email your story to Vince at vince@gileadchicago.org. JOIN US IRL!Whoever you are, whatever your story is, you are welcome with us.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠Sign up for our newsletter here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ to stay up to date on when and where our services are happening! (Sometimes that info changes, so the newsletter is the best way to keep up.)ABOUT USJust to make sure this is clear, we'd like to reiterate that everyone is welcome at our church. EVERYONE. We believe that human diversity of race, ethnicity, sexual orientation, gender identity, and gender expression — not to mention age, ability, relationship status, size — is necessary to reflect the fullness of God. Whoever you are, whatever your story is, you are welcome here. ***This episode was originally recorded on March 23, 2025

In this Bible Story, civil war breaks out between the tribe of Benjamin and the rest of the Israelites. Yet God is faithful and promises to restore Benjamin and the city of Gilead. This story is inspired by Judges 20-21. Go to BibleinaYear.com and learn the Bible in a Year.Today's Bible verse is Judges 21:6 from the King James Version.Episode 72: Disgusted and terrified at what had happened in Benjamin, the rest of Israel had decided to assemble and seek the will of God for what they should do. As one nation, the 11 other tribes rose against the tribe of Benjamin. Peaceful negotiations were fruitless and war ensued. Battle after battle, Israel lost to the tribe of Benjamin until God gave them victory. But no celebration followed this victory, instead, there was mourning as Israel had brought one of its brothers to the brink of extinction. Our vengeance, if even for a right cause often brings more harm than good.Hear the Bible come to life as Pastor Jack Graham leads you through the official BibleinaYear.com podcast. This Biblical Audio Experience will help you master wisdom from the world's greatest book. In each episode, you will learn to apply Biblical principles to everyday life. Now understanding the Bible is easier than ever before; enjoy a cinematic audio experience full of inspirational storytelling, orchestral music, and profound commentary from world-renowned Pastor Jack Graham.Also, you can download the Pray.com app for more Christian content, including, Daily Prayers, Inspirational Testimonies, and Bedtime Bible Stories.Visit JackGraham.org for more resources on how to tap into God's power for successful Christian living.Pray.com is the digital destination of faith. With over 5,000 daily prayers, meditations, bedtime stories, and cinematic stories inspired by the Bible, the Pray.com app has everything you need to keep your focus on the Lord. Make Prayer a priority and download the #1 App for Prayer and Sleep today in the Apple app store or Google Play store.Executive Producers: Steve Gatena & Max BardProducer: Ben GammonHosted by: Pastor Jack GrahamMusic by: Andrew Morgan SmithBible Story narration by: Todd HaberkornSee omnystudio.com/listener for privacy information.

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her. Now in its 6th and final season, BGN breaks down in weekly recaps, our thoughts behind this provocative series. Hosts: Angelica Monk and Stacey Yvonne  Music by: Sammus Edited by: Jamie Broadnax

The Gaslit Nation Media Committee, a watchdog against access journalism and regime propaganda, has developed this essential guide. We urge all members of the media to reject complicity in the erosion of democracy.   The American crisis is a global struggle between democracy and fascism—one that threatens the entire world. Each of us has a role in defending freedom. If you work in media, use this guide to safeguard your integrity, your liberty, and the values we cherish—before it's too late. Doing your job well can save lives and democracy.   1. Don't Bury the Lede: Call It an Illegal Tech-Backed Coup To build trust, stick to the facts. When Trump's administration acts illegally, say it—especially in the headline. Call it what it is: a tech-backed coup that exposes Americans' most sensitive data and replaces federal workers with unsecured A.I. to establish a new surveillance state. 2. Make Private Prison Execs Famous Investigate the financial interests behind Trump's immigration system—expose executives, board members, and their connections. Pursue them with cameras; they can't hide behind profits while lives are ruined and civil liberties eroded. 3. Fascism Needs Ignorance From dismantling the Department of Education to the “War on Woke” in universities, Trump continues delegitimizing education. This isn't about competition with other countries—it's about giving everyone the chance to grow as independent thinkers who reject fascism. 4. Follow the Money Investigate Trump's major donors and their role in Musk's illegal purge of government services. Hold them accountable—ask how they view their investments amid the chaos. Track their contracts and regulatory benefits. 5. Expose National Security Threats Trump removed key military officials who prevented unlawful actions. Without them, who will stop him? Trump holds the nuclear football, cozying up to adversaries, sending bombs to Israel, and threatening wars against Canada and Greenland. Focus on how our adversaries are taking advantage. 6. Kleptowatch Focus on how companies exploit customers through greedflation and Amazon's payola for search visibility. While the Biden administration has much to answer for, the media must spotlight the absence of enforcement of investigations brought by Lina Khan and Tim Wu, leaving corporate kleptocrats unchecked. 7. Media Must Thoroughly Cover Media Journalists must cover media attacks, including blocked access to info and censorship (e.g., Ann Telnaes at WaPo). Report on media ecosystem shifts, address bias, and clarify distinctions between reporting, opinion, and lies. Provide context on media ownership. 8. Draw Historical Parallels Trump, Musk, and allies are enacting policies similar to dictators like Hitler, Mussolini, and Stalin. The media must challenge their unfounded assertions. They are attacking the press and critics, reminiscent of regimes like Pol Pot's and Rwanda's genocide. 9. Trump is Trying to Turn America into an Autocracy: Act Like It Columbia Journalism Review shared 10 essential tips for journalists reporting from autocracies. Share these with your teams, including your company's lawyers—killing big stories and obeying in advance is self-destructive. 10. Shine a Light on Private Prisons The private prison industry needs scrutiny, especially with Trump's lack of oversight. Innocent people are caught in reckless immigration raids as the system grows unchecked. Regular coverage of Guantanamo Bay is crucial due to its history of unlawful detention and Trump's plan for a prison camp there for 30,000 people. 11. Gilead is Here The media has abandoned calling out Trump's toxic masculinity regarding reproductive rights and civil rights. Raise awareness of the deadly consequences for women, including trans women, and all nonwhite people. 12. Access Journalism is Betrayal Fascism's history includes journalists from major outlets becoming "masters of euphemism," (to quote Gareth Jones), downplaying atrocities and broken laws to protect access. History will remember you for doing your job or being bought. Doing your job well can save lives and democracy. 13. Family Members Deserve Special Attention Trump's administration is granting lucrative positions to family members of allies and donors, giving them undue influence over policy. These self-dealing networks must be mapped and exposed. 14. Unmask Voter Suppression Election analysis must address gerrymandering, unfair Senate representation favoring "red states," the Electoral College designed to protect elites, and the gutting of the Voting Rights Act. Don't treat our voter suppression crisis like "horse race" politics. 15. Focus on the 1% Expose extreme wealth inequality—how the 1% dodge taxes and exploit loopholes to preserve their wealth. Put a spotlight on how inequality fuels authoritarianism and is a direct threat to democracy. 16. Cover Protests Highlight actions challenging the White House's destructive crimes. People need to see that citizens care about the laws being broken by Trump's administration and that they're not alone. 17. They're Testing Boundaries: Say It When something is "unprecedented," that means they're testing boundaries, to see what they can get away with. Say it. 18. The Weird Fights Matter Trump renaming the Gulf of Mexico to the Gulf of America may seem "weird," but it's part of the fascist pageantry, like Mussolini's famous eyeliner and Putin's shirtless photos. Look to experts in autocracy to see which stories are being used as a distraction and which stories are important to cover.  An expanded version of the Gaslit Nation Media Guide can be found here: https://www.gaslitnationpod.com/media-guide   For More: Ten Tips for Reporting in an Autocracy American journalists have much to learn from colleagues in countries where democracy has been under siege. https://www.cjr.org/political_press/ten-tips-for-reporting-in-an-autocracy.php   Want to enjoy Gaslit Nation ad-free? Join our community of listeners for bonus shows, ad-free episodes, exclusive Q&A sessions, our group chat, invites to live events like our Monday political salons at 4pm ET over Zoom, and more! Sign up at Patreon.com/Gaslit!   Music Credit: "Tafi Maradi no voice" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/